The GGGGCC repeat expansion in C9ORF72 is the most common cause of ALS and FTD, accounting for about 10% of each disease worldwide [1] [2] [3] [4] . In the central nervous system (CNS), neurons and microglia express the highest levels of C9ORF72 (ref. 5), suggesting that C9ORF72 acts, at least in part, in a cell autonomous manner and that effects in neurons are an important source of disease etiology. Studies showing that the repeat expansion generates neurotoxic species, including nuclear RNA foci 6-8 , RNA/DNA G-quadruplexes 9 and dipeptide repeat proteins (DPRs) [10] [11] [12] , have oriented the field toward a therapeutic focus on blocking the toxicity of these products [6] [7] [8] 13, 14 . However, these strategies have not fully rescued the degeneration of patient-derived neurons 7, 13 . Moreover, tandem GGGGCC repeats are transcribed from over 80 other genomic locations in human spinal motor neurons (Supplementary Tables  1 and 2 ), yet genetic studies have not linked repeat expansions in these regions to ALS and FTD. In addition, hexanucleotide-repeat -mediated toxicity in mice requires supraphysiological expression levels or a specific genetic background [14] [15] [16] . These observations suggest that there are additional pathogenic triggers caused by repeat expansion in C9ORF72.
The GGGGCC repeat expansion in C9ORF72 is the most common cause of ALS and FTD, accounting for about 10% of each disease worldwide [1] [2] [3] [4] . In the central nervous system (CNS), neurons and microglia express the highest levels of C9ORF72 (ref. 5) , suggesting that C9ORF72 acts, at least in part, in a cell autonomous manner and that effects in neurons are an important source of disease etiology. Studies showing that the repeat expansion generates neurotoxic species, including nuclear RNA foci [6] [7] [8] , RNA/DNA G-quadruplexes 9 and dipeptide repeat proteins (DPRs) [10] [11] [12] , have oriented the field toward a therapeutic focus on blocking the toxicity of these products [6] [7] [8] 13, 14 . However, these strategies have not fully rescued the degeneration of patient-derived neurons 7, 13 . Moreover, tandem GGGGCC repeats are transcribed from over 80 other genomic locations in human spinal motor neurons (Supplementary Tables  1 and 2 ), yet genetic studies have not linked repeat expansions in these regions to ALS and FTD. In addition, hexanucleotide-repeat -mediated toxicity in mice requires supraphysiological expression levels or a specific genetic background [14] [15] [16] . These observations suggest that there are additional pathogenic triggers caused by repeat expansion in C9ORF72.
The repeat expansion suppresses the production of C9ORF72 protein by inhibiting transcription 3, 4, 6, 7, 9, 17 , raising the possibility that haploinsufficiency for C9ORF72 activity triggers disease pathogenesis. Consistent with this hypothesis, elimination of C9ORF72 activity a r t i c l e s 3 1 4 VOLUME 24 | NUMBER 3 | MARCH 2018 nature medicine alters myeloid cell behavior in mice 14, 18, 19 , and in vitro studies have suggested that C9ORF72 activity may enhance autophagy 20, 21 . However, C9ORF72-deficient mice do not display overt neurodegenerative phenotypes 14, 18, 19, 22 . Moreover, no studies have shown that reduced C9ORF72 activity leads to the degeneration of C9ORF72 ALS patient-derived motor neurons nor have any studies provided direct evidence identifying a cellular pathway through which C9ORF72 activity modulates neuronal survival. In addition, a patient homozygous for the C9ORF72 repeat expansion had clinical and pathological phenotypes that were severe, but nonetheless did not fall outside of the range of heterozygous patients, leaving it uncertain whether reductions in C9ORF72 protein levels directly correlate with disease severity 23 . Thus, the role of the C9ORF72 protein in C9ORF72 ALS/FTD disease pathogenesis remains unclear.
RESULTS

C9ORF72 patient iMNs recapitulate ALS disease processes
To study the pathogenic mechanism of the C9ORF72 repeat expansion in human motor neurons, we used the forced expression of the transcription factors Ngn2, Isl1, Lhx3, NeuroD1, Brn2, Ascl1 and Myt1l to convert control and C9ORF72 ALS/FTD patient induced pluripotent stem cells (iPSCs; for iPSC characterization, see Supplementary Fig. 1 and Supplementary Tables 3 and 4) into iMNs ( Supplementary  Fig. 2a,b) 10, 24 . Control and patient iMNs labeled with an Hb9::RFP + lentiviral reporter construct ( Supplementary Fig. 2b-d) 25 coexpressed spinal motor neuron markers, including TUJ1, HB9, and VACHT, were produced at similar rates amongst different iPSC lines, and possessed the same electrophysiological properties as motor neurons ( Supplementary Fig. 2c-i) . Depolarizing voltage steps induced currents characteristic of sodium and potassium channels, and iMNs fired single or repetitive action potentials (patient, 90%, n = 10; control, 100%, n = 10; Supplementary Fig. 2g-i) . When co-cultured with primary chick muscle, channel-rhodopsin-expressing control and patient iMNs repeatedly induced myotube contraction following depolarization with green light, indicating they formed neuromuscular junctions and actuated muscle contraction ( Supplementary  Fig. 2j and Supplementary Videos 1 and 2).
To determine whether C9ORF72 iMNs recapitulate neurodegenerative ALS processes, we examined their survival by performing longitudinal tracking of Hb9::RFP + iMNs (Fig. 1a) . This approach enabled us to distinguish differences in neurogenesis from differences in survival, which could not be addressed using previously reported cross-sectional analyses 6, 7, 10, 26 . In basal neuronal medium supplemented with neurotrophic factors, control and C9ORF72 patient iMNs survived equally well (Fig. 1b, Supplementary Fig. 3a and Supplementary Tables 5 and 6). Given that human C9ORF72 ALS patients have elevated glutamate levels in their cerebrospinal fluid (possibly triggered by DPR-mediated aberrant splicing of the astrocytic excitatory amino acid transporter 2 EAAT2) 4, 27 , we stimulated iMN cultures with a high-glutamate pulse (12-h treatment, 10 µM glutamate). This initiated a robust degenerative response in patient, but not control, iMNs (Fig. 1c-e and Supplementary Videos 3 and 4) that was consistent across lines from multiple patients (n = 6 patients) and controls (n = 4 controls) (Fig. 1c,d and Supplementary Fig. 3d,e) . Although iMN survival varied slightly between live imaging systems and between independent experiments as a result of the lengthy time course of neurodegeneration, the relative difference between control and C9-ALS patient iMNs was consistent (Nikon Biostation CT; Fig. 1c ; Molecular Devices ImageExpress; Supplementary Fig. 3b ). Moreover, iMNs from different iPSC lines derived from the same donor behaved similarly, suggesting that genotypic differences accounted for these effects (Supplementary Fig. 3c ). Treatment with glutamate receptor antagonists during glutamate administration prevented patient iMN degeneration (Fig. 1f) . Alternatively, withdrawal of neurotrophic factors without glutamate stimulation also caused rapid degeneration of patient iMNs (n = 3 patients; Fig. 1g and Supplementary Fig. 3f ).
To determine whether the survival difference between C9ORF72 patient iMNs and controls was specific to our transcription-factorbased reprogramming approach, we also measured the survival of Hb9::RFP + control and C9ORF72 patient motor neurons derived from iPSCs by small molecule activation of the Sonic Hedgehog and retinoic acid signaling pathways 28 ( Supplementary Fig. 3g,h ). Similarly to iMNs, morphogen-generated motor neurons showed a significant survival difference between C9ORF72 patients and controls (P < 0.0001 for control versus C9ORF72 +/− , C9ORF72 −/− or C9ORF72 patients; Supplementary Fig. 3i-l) .
To determine whether patient iMN degeneration results from bona fide ALS disease processes specific for motor neurons, we measured the survival of induced dopaminergic neurons (iDAs) generated by expression of FoxA2, Lmx1a, Brn2, Ascl1 and Myt1l 29 . These neurons expressed high levels of tyrosine hydroxylase, indicating that they had established a key aspect of the dopamine synthesis pathway and were distinct from iMNs, which do not express this enzyme 24 ( Supplementary  Fig. 3m,n) . Unlike iMN cultures, iDA cultures from C9ORF72 patients (n = 2 patients) did not show reduced survival compared with controls (n = 2 controls) in either glutamate treatment and neurotrophic factor withdrawal conditions ( Fig. 1h and Supplementary Fig. 3o ), indicating that the in vitro neurodegenerative phenotype elicited by the C9ORF72 mutation is selective for motor neurons.
C9ORF72 is haploinsufficient in ALS
Consistent with previous studies 3, 4, [6] [7] [8] , patient iMNs (n = 5 patients) showed reduced C9ORF72 expression compared with controls (n = 3; Fig. 2a and Supplementary Figs. 4a and 5b). Although previous studies have linked low C9ORF72 levels to changes in vesicle trafficking or autophagy 18, 20, 21, [30] [31] [32] , it remains unknown whether the loss of C9ORF72 protein directly contributes to degeneration. Thus, we reexpressed C9ORF72 (isoform A or B) in iMNs using a retroviral cassette ( Supplementary Fig. 4b ) and found that both isoforms rescued C9ORF72 patient iMN survival in response to glutamate treatment (n = 3 patients; Fig. 2b and Supplementary Fig. 4c ). This effect was specific for C9ORF72 iMNs, as forced expression of C9ORF72 did not rescue SOD1A4V iMN survival (Fig. 2c) or improve the survival of control iMNs (n = 2 controls; Fig. 2d and Supplementary Fig. 4d ).
To confirm that reduced C9ORF72 protein levels are sufficient to cause neurodegeneration, we used CRISPR/Cas9-mediated genome editing to introduce a frameshift mutation into one or both alleles of C9ORF72 in control iPSCs ( Fig. 2e and Supplementary Fig. 4e ). Quantitative PCR (qPCR) revealed that targeting one allele reduced C9ORF72 transcript levels as a result of nonsense-mediated decay, and transcript levels were more severely reduced in homozygous mutant cells (Supplementary Fig. 4f ). Frameshift mutations also decreased C9ORF72 protein expression ( Supplementary Figs. 4g and 5c). RNA sequencing of flow-purified Hb9::RFP + iMNs revealed that targeting C9ORF72 did not substantially alter the expression of the top ten genes with predicted off-target sites for the CRISPR guide RNA ( Supplementary Fig. 4h and Supplementary Table 7 ). In addition, expression levels of the 20 genes nearest C9ORF72 on chromosome 9 were largely unperturbed in either the C9ORF72 +/−and C9ORF72 −/− iMNs, indicating that this approach specifically inactivated C9ORF72 (Supplementary Fig. 4i ).
Eliminating C9ORF72 protein expression from one or both alleles reduced iMN survival to levels comparable to those of patient iMNs (Fig. 2f) . Antisense oligonucleotide (ASO)-mediated suppression of C9ORF72 expression levels also reduced control iMN survival ( Fig. 2g and Supplementary Fig. 4j ), suggesting that reduced iMN survival was not a result of an off-target effect of the CRISPR/Cas9 genome editing. Exogenously restoring C9ORF72 expression in C9ORF72 +/− and C9ORF72 −/− iMNs rescued survival ( Supplementary Fig. 4k,l) , verifying that depletion of C9ORF72 caused the observed neurodegeneration.
To determine whether transcriptional changes in C9ORF72 +/− and C9ORF72 −/− iMNs also reflect the contribution of C9ORF72 protein levels to neurodegeneration, we performed RNA sequencing on flowpurified Hb9::RFP + iMNs from C9ORF72 +/− , C9ORF72 −/− and isogenic control iMNs, as well as C9ORF72 patient iMNs (Supplementary Table 7) , and compared them to existing RNA-seq data from postmortem tissue 33, 34 . When examining consensus genes that were differentially expressed compared with controls in all C9ORF72 patient postmortem data sets (from GSE56504 and GSE67196) 33, 34 , both C9ORF72 +/− and C9ORF72 patient iMNs shared similar gene expression changes to the postmortem tissue (Supplementary Fig. 6 ). Thus, a reduction in C9ORF72 levels induces disease-associated transcriptional changes observed in C9ORF72 patient postmortem samples.
Reduced C9ORF72 activity disrupts lysosomal biogenesis in motor neurons
Determining the functional pathway in which C9ORF72 acts may enable design of function-directed therapies. C9ORF72 displays limited structural homology to differentially expressed in normal and neoplasia (DENN)-domain containing proteins 35 , many of which modulate RAB GTPase activity and vesicle trafficking 36 .
There are conflicting reports as to whether C9ORF72 levels have a greater effect on endosomes or lysosomes and whether C9ORF72 levels affect vesicle trafficking in neurons in the same way as in cell lines 18, 21, [30] [31] [32] 37 . In addition, the functional role of C9ORF72 in patient motor neurons is unclear.
To examine C9ORF72 function, we determined its localization in iMNs. We first used an HA-tagged C9ORF72 construct to verify that the C9ORF72 antibody specifically recognizes C9ORF72 in cells (Supplementary Fig. 7a ). In iMNs, C9ORF72 colocalized to cytoplasmic puncta, and ASO-mediated knockdown of C9ORF72 expression reduced the number of antibody-detected cytoplasmic puncta in iMNs, indicating that the antibody specifically recognizes C9ORF72 in these puncta (Supplementary Fig. 7b,c) . Super-resolution microscopy . n = 50 iMNs per line for two control and three C9-ALS lines, iMNs quantified from three biologically independent iMN conversions per line. (e) iMNs at day 22 in excess glutamate. This experiment was repeated three times with similar results. (f,g) Survival of control and C9-ALS iMNs in excess glutamate with glutamate receptor antagonists (f) or without neurotrophic factors (g). n = 50 iMNs per line for two control and three C9-ALS lines, iMNs quantified from three biologically independent iMN conversions per line. (h) Survival of iDAs in excess glutamate. n = 50 iMNs per line for two control and two C9-ALS lines, iMNs quantified from three biologically independent iMN conversions per line. Except in d, each trace includes neurons from at least two donors with the specified genotype; see Online Methods. Scale bar represents 100 µm (e). All iMN survival experiments were analyzed by two-sided log-rank test and statistical significance was calculated using the entire survival time course. iMN survival experiments in b-g were performed in a Nikon Biostation and experiments in h were performed in a Molecular Devices ImageExpress.
a r t i c l e s and z-stack imaging showed that about 80% of the C9ORF72-positive vesicles also expressed the early endosomal proteins RAB5 and EEA1 ( Fig. 3a and Supplementary 7d-h ). Only rarely did C9ORF72 colocalize with the lysosomal marker LAMP1 (20%; Supplementary  Fig. 7e ), and control and patient iMNs showed similar C9ORF72 localization (Supplementary Fig. 7h ). We performed density gradient centrifugation on lysates from iPSC-derived motor neurons to separate light (endosomal) and heavy (lysosomal) membrane fractions. C9ORF72 co-segregated with EEA1 and not LAMP1, supporting the notion that C9ORF72 localizes predominantly in early endosomes ( Fig. 3b and Supplementary Fig. 5d ). In addition, we found that C9ORF72 isoform B bound strongly to an immobilized N-terminal fragment of EEA1 (Supplementary Fig. 7i ). C9ORF72 isoform A did not interact as strongly with EEA1 ( Supplementary Fig. 7i ). The fact that not all EEA1 + vesicles contained high levels of C9ORF72 is consistent with this hypothesis and suggests that C9ORF72 may not localize to all types of EEA1 + vesicles (Fig. 3a) .
To determine whether a deletion of C9ORF72 or the C9ORF72 repeat expansion caused changes in endosomal trafficking in motor neurons, we examined the number of early endosomes (RAB5 + , EEA1 + ), late endosomes (RAB7 + ) and lysosomes (LAMP1 + , LAMP2 + , LAMP3 + ) in control, C9ORF72 patient, C9ORF72 +/− and C9ORF72 −/− iMNs. We observed the most significant difference in the lysosomal population, with C9ORF72 patient iMNs (n = 4 patients) having fewer LAMP1 + , LAMP2 + and LAMP3 + vesicles than control iMNs (n = 4 controls; Fig. 3c,d and Supplementary Fig. 8a-d) . C9ORF72 +/− and C9ORF72 −/− also harbored fewer LAMP1 + , LAMP2 + and LAMP3 + vesicles than isogenic control iMNs, indicating that reduced C9ORF72 levels alone leads to a loss of lysosomes (Fig. 3c,e,f and Supplementary  Fig. 8a-d) . ASO-mediated knockdown of C9ORF72 expression also decreased lysosome numbers in iMNs (Supplementary Fig. 8e ). Although membrane fractionation revealed that control and patient iMNs have similar amounts of LAMP2 in the lysosomal membrane fraction (Supplementary Fig. 8f) , analysis of the immunofluorescence intensity of LAMP proteins suggests that this is likely a result of the C9ORF72 patient and C9ORF72 +/− iMNs having a higher concentration of LAMP proteins in their lysosomal membranes, possibly as a result of fewer lysosomes being present (Supplementary Fig.  8g ). Using electron microscopy to identify lysosomes by their high election density 38 , we verified that the vesicles reduced in C9ORF72-deficient cells were lysosomes (Fig. 3g-i) . Forced expression of either C9ORF72 isoform restored the number of LAMP1 + , LAMP2 + and LAMP3 + lysosomes in patient (n = 4 patients) and C9ORF72-deficient iMNs (Fig. 3c-f and Supplementary Fig. 8a-h ). To determine a r t i c l e s whether a loss of C9ORF72 activity reduces lysosome numbers in motor neurons in vivo, we measured the number of lysosomes in spinal motor neurons in Nestin-Cre-Stop-Flox-C9orf72 mice 22 . We found significantly fewer Lamp1 + lysosomes in C9orf72 −/− motor neurons than in control motor neurons (Fig. 3j,k) . During lysosomal biogenesis, lysosomal proteins are transported in mannose-6-phosphate receptor (M6PR) + vesicles from the transGolgi network to early and late endosomes for eventual incorporation into lysosomes 39 . Disruption of M6PR + vesicle trafficking can lead to a reduction in lysosome numbers 40 and altered localization of M6PR + vesicles 41 . In control iMNs (n = 3 controls), M6PR + vesicles were distributed loosely around the perinuclear region and, to a lesser extent, in the non-perinuclear cytosol (Supplementary Fig. 9a,b) . In contrast, C9ORF72 patient (n = 4 patients), C9ORF72 +/− and C9ORF72 −/− iMNs frequently harbored densely packed clusters of M6PR + vesicles ( Supplementary Fig. 9a,b) . This was not a result of a reduced number of M6PR + vesicles in patient and C9ORF72-deficient iMNs (Supplementary Fig. 9c ). Forced expression of C9ORF72 isoform B restored normal M6PR + vesicle localization in patient (n = 4 patients) and C9ORF72-deficient iMNs, confirming that a lack of C9ORF72 activity induced this phenotype ( Supplementary Fig. 9a,b) .
Live imaging of iMNs expressing a M6PR-GFP fusion protein that localizes to M6PR + vesicles 42 confirmed that C9ORF72 patient and C9ORF72-deficient iMNs possessed increased numbers of M6PR + vesicle clusters and that overexpression of C9ORF72 isoform A or B rescued this phenotype ( Supplementary Fig. 9c-g and Supplementary Videos 5-9). Clusters did not disperse over the time course of the assay, suggesting that they were relatively stable and not in rapid flux (Supplementary Videos 5-9 ). In addition, M6PR + puncta moved with a slower average speed in C9ORF72 patient and C9ORF72 +/− iMNs than in controls ( Supplementary Fig. 9h,i) . Thus, reduced C9ORF72 levels lead to fewer lysosomes in motor neurons in vitro and in vivo, and this may be a result of, in part, altered trafficking of M6PR + vesicles.
Low C9ORF72 activity sensitizes iMNs to glutamate Our iMN survival results (Fig. 1c-e) suggest that the repeat expansion alters iMN glutamate sensing. In cortical neurons, homeostatic synaptic plasticity is maintained through endocytosis and subsequent lysosomal degradation of glutamate receptors in response to chronic glutamate signaling 43, 44 . Defects in this process lead to the accumulation of glutamate receptors on the cell surface 43, 44 .
Immunostaining revealed that C9ORF72 +/− and C9ORF72 −/− iMNs contained elevated levels of NMDA (NR1) and AMPA (GLUR1) receptors on neurites and dendritic spines compared with control iMNs under basal conditions (Fig. 4a,c,d and Supplementary Figs. 5b and  10a,c-e,g,h,j,k) . In addition, control iMNs treated with C9ORF72-specific ASOs displayed increased numbers of NMDA and AMPA receptors in their neurites (Supplementary Fig. 10l,m) . C9ORF72 patient iMNs (n = 3 patients) also showed elevated NR1 and GLUR1 levels as compared with controls (n = 3 controls), and forced expression of C9ORF72 isoform B reduced glutamate receptor levels in patient iMNs (n = 3 patients) compared with controls (n = 3 controls) (Fig. 4a-c and Supplementary Fig. 10a-h ). mRNA levels of NR1 (GRIN1) and GLUR1 (GRIA1) were not elevated in flowpurified C9ORF72 +/− iMNs, indicating that increased transcription could not explain the increased glutamate receptor levels ( Supplementary Fig. 10n ).
To confirm that glutamate receptor levels were increased on the surface of C9ORF72 +/− and C9ORF72 patient iMNs, we used CRISPR/Cas9 editing to introduce a Dox-inducible polycistronic cassette containing NGN2, ISL1 and LHX3 into the AAVS1 safe-harbor locus of control, C9ORF72 +/− and C9ORF72 patient iPSCs. This enabled large-scale production of iMNs that expressed motor neuron markers and had transcriptional profiles similar to iMNs made using our full set of seven transcription factors ( Supplementary Fig. 11 ). Using this approach, we quantified the amount of surface-bound NR1 by immunoblotting after using surface protein biotinylation to isolate membrane-bound proteins. This confirmed that surface NR1 levels were higher on C9ORF72 +/− and C9ORF72 patient iMNs (n = 2 patients) than controls (n = 3 controls) ( Fig. 4e-h, Supplementary Fig. 5g,h ).
To determine whether reduced C9orf72 levels leads to glutamate receptor accumulation in vivo, we examined spinal motor neurons in Nestin-Cre-Stop-Flox-C9orf72 mice, in which C9orf72 was deleted 22 . Immunofluorescence analysis indicated that Nr1 (NMDA) and GluR1 (AMPA) levels were elevated in C9orf72-null motor neurons ( Supplementary Fig. 12a,b) . To confirm these findings, we isolated postsynaptic densities from the spinal cords of control and C9orf72 knockout mice. Postsynaptic density fractions contained glutamate receptors and PSD-95, but not p53 or synaptophysin, indicating that they were enriched for postsynaptic density proteins (Supplementary Figs. 5i and 12c). Immunoblotting revealed that postsynaptic densities in C9orf72 knockout mice contained significantly higher levels of Nr1 and Glur1 than control mice (Fig. 4i,j and Supplementary Fig. 5j ).
To determine whether glutamate receptor accumulation occurs on C9ORF72 patient motor neurons in vivo, we measured glutamate receptor expression in ventral horn neurons in lumbar spinal cord samples from three C9ORF72 ALS patients and three unaffected controls. We identified motor neurons by size and confirmed that most neurons selected in this manner expressed CHAT and SMI-32 ( Supplementary  Fig. 12d ). Spinal motor neurons from the C9ORF72 ALS patients displayed higher NR1 levels than control neurons (Supplementary Fig.  12e ). In addition, postsynaptic densities isolated from the motor cortices of C9ORF72 patients had higher levels of NR1 and GLUR1 than controls (Fig. 4k,l and Supplementary Fig. 5k) .
To determine whether the extra glutamate receptors were functional, we used Gcamp6 (ref. 45 ) to measure calcium influx into iMNs in response to glutamate. Glutamate triggered more frequent calcium influxes in C9ORF72 patient (n = 3 patients) and C9ORF72 +/− iMNs than controls (n = 3 controls) ( Fig. 4m and Supplementary Videos 10-12).
Given that glutamate receptor activation and neuronal firing both induce calcium influx, we determined their relative contributions to the increased Gcamp6 activation by using the ion channel inhibitors TTX and TEA to block neuronal firing. C9ORF72 +/− iMNs still displayed more frequent Gcamp6 activation than C9ORF72 +/+ iMNs ( Supplementary Fig. 13a ), indicating that part of the hyperexcitability is a result of increased glutamate receptor activation. To determine which receptors were responsible for the increased glutamate response, we tested small-molecule agonists of specific glutamate receptor subtypes. Activation of NMDA, AMPA and kainate receptors was higher in C9ORF72 +/− iMNs than in controls ( Supplementary Fig. 13a ).
Removal of TTX and TEA during glutamate receptor agonist treatment revealed additional increases in Gcamp6 activation in C9ORF72 +/− iMNs compared with controls, suggesting that C9ORF72 +/− iMNs also fire action potentials more frequently than controls ( Supplementary Fig. 13a ), although we did not detect large changes in sodium or potassium current amplitudes in C9ORF72 +/− iMNs ( Supplementary Fig. 13b,c) . To determine whether increased 
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Immunoblotting analysis of surface NR1 after surface protein biotinylation in control (e-h), C9ORF72 +/− (e,f) and C9-ALS patient (g,h) iMNs generated with three factors (NGN2, ISL1 and LHX3). In f, n = 4 biologically independent iMN conversions from CTRL2 and two biologically independent iMN conversions from the C9ORF72 +/− line. Data are presented as mean ± s.d. In h, two-tailed Mann-Whitney test. n = 11 biologically independent motor neuron cultures from 11 independent control lines and 4 biologically independent motor neuron cultures from 4 independent C9-ALS patient lines. a r t i c l e s neuronal activity, resulting in part from elevated glutamate receptor levels, contributes to neurodegeneration in C9ORF72 patients and C9ORF72 +/− iMNs, we measured iMN survival in the presence or absence of retigabine. Retigabine is approved by the US Food and Drug Administration for the treatment of epilepsy and reduces neuronal excitability by activating Kv7 potassium channels 46 . In the glutamate treatment assay, retigabine increased the survival of C9ORF72 patient (n = 2 patients) and C9ORF72-deficient iMNs, but not that of controls (n = 2 controls; Supplementary Fig. 13d-g ).
Although C9orf72 knockout mice do not show overt neurodegeneration, gain-of-function disease processes may trigger neurodegeneration through mechanisms induced by reduced C9ORF72 levels. For example, DPRs cause mis-splicing of the EAAT2 glutamate transporter in astrocytes, which could increase excitotoxicity in neurons with elevated glutamate receptor levels 12 . To determine whether DPRs alter glutamate uptake by astrocytes, we compared glutamate uptake in human primary astrocytes expressing either GFP or GR 50 (50 tandem repeats of glycinearginine)-GFP. Indeed, GR 50 -GFP significantly impaired glutamate uptake by astrocytes (P = 0.0055; Supplementary Fig. 13h ).
Low C9ORF72 activity sensitizes iMNs to DPR toxicity
We wondered whether reduced C9ORF72 activity renders motor neurons vulnerable to other insults that might be exacerbated by impaired endosomal-lysosomal system function, such as DPR toxicity. Without excess glutamate treatment, C9ORF72 +/− , C9ORF72 −/− and C9ORF72 patient iMN survival was similar to that of control iMNs (Fig. 5a-d and Supplementary Fig. 14a,b) . Exogenous expression of 50 tandem repeats of proline-arginine (PR 50 ) or GR 50 DPRs using cassettes that do not contain the GGGGCC repeat expansion induced control iMN degeneration (Fig. 5a,b) . Notably, C9ORF72 +/− , C9ORF72 −/− and C9ORF72 patient iMNs (n = 2 patients) degenerated significantly faster than controls in response to PR 50 or GR 50 expression (Fig. 5a-d and Supplementary Fig. 14a,b) .
Because C9ORF72 activity is required to maintain normal lysosomal function, we measured the effect of C9ORF72 activity on PR 50 clearance by monitoring the clearance of PR 50 -Dendra2 fusion proteins in C9ORF72 −/− iPSC-derived fibroblasts with or without exogenous C9ORF72. Dendra2 is a GFP that irreversibly converts to red fluorescence when exposed to blue light, enabling quantification of its degradation 47 . PR 50 -Dendra2 formed discrete punctae within cells, indicating that Dendra2 did not prevent intracellular aggregation of PR 50 (Supplementary Fig. 14c ). Expression of C9ORF72-T2A-GFP in C9ORF72 −/− iPSC-derived fibroblasts substantially enhanced the decay of PR 50 -Dendra2 fluorescence over that of GFP alone ( Supplementary  Fig. 14d ). To determine whether C9ORF72 activity modulates DPR aggregate clearance in human motor neurons, we compared the decay of PR 50 -Dendra2 in C9ORF72 +/+ and C9ORF72 +/− iMNs ( Fig. 5e and Supplementary Fig. 14e) . Consistent with the hypothesis that C9ORF72 activity promotes DPR aggregate clearance, PR 50 -Dendra2 decayed significantly slower in C9ORF72 +/− iMNs (Fig. 5e) .
To measure the effect of C9ORF72 activity on endogenous DPR levels in human motor neurons, we quantified endogenous PR + puncta in C9-ALS iMNs with or without C9ORF72 overexpression. Using a validated anti-PR antibody 10, 48 , we found that the majority of PR + punctae were localized in the nucleus (Fig. 5f) , although we also detected cytoplasmic PR + punctae to a larger extent than we had previously observed with exogenous PR 50 (ref. 10) . C9-ALS iMNs (n = 2 patients) had higher levels of nuclear PR + puncta than controls (n = 2 controls; Fig. 5f,g ) and overexpression of C9ORF72 isoform B significantly reduced the number of PR + puncta in C9-ALS iMNs (Fig. 5f,h ).
Given our observation that iMNs with reduced C9ORF72 levels are hypersensitive to DPR toxicity, we wondered whether this might be a result of a general disruption of protein turnover by DPRs. However, PR 50 -GFP expression did not impair turnover of APP or Tau (Supplementary Figs. 5l and 14f,g) . Thus, the neurotoxicity caused by DPRs that accumulate rapidly in C9-ALS motor neurons resulting from reduced C9ORF72 levels is not a result of global disruption of protein turnover.
Small molecule and genetic regulators of endosomal trafficking rescue patient iMN survival Therapeutic strategies in development for C9ORF72 ALS/FTD target gain-of-function mechanisms. These include ASOs 6-8 and small molecules 13 that disrupt RNA foci formation. However, these approaches do not fully rescue neurodegeneration in human-patient-derived neurons [6] [7] [8] 13 , indicating that replacing C9ORF72 function or new therapeutic targets may be required.
We performed a phenotypic screen to identify small molecules that rescue C9ORF72 patient iMN survival (Fig. 6a) . To enrich for chemicals that might replace C9ORF72 function, we screened 800 bioannotated compounds targeting diverse cellular processes, including vesicle trafficking.
Among four reproducible hit compounds, we identified a PIKFYVE kinase inhibitor (YM201636) that significantly increased C9ORF72 patient iMN survival (n = 2 patients) (Fig. 6b,c and Supplementary  Fig. 15a ). PIKFYVE is a lipid kinase that converts phosphatidylinositol 3-phosphate (PI3P) into phosphtidylinositol (3,5)-bisphosphate (PI(3,5)P 2 ) 49 (Fig. 6f) . PI3P is primarily generated by PI3-kinases recruited to early endosomes by RAB5, and PI3P anchors EEA1 to early endosomes to drive endosomal maturation 50 (Fig. 6f) . Following endosomal maturation into lysosomes, PI3P drives fusion of lysosomes with autophagosomes 51 . PIKFYVE regulates PI3P levels by converting PI3P into PI(3,5)P 2 (ref. 50) , which disfavors lysosomal fusion with endosomes and autophagosomes 51, 52 . Thus, inhibition of PIKFYVE increases autophagosome-lysosome fusion 51 and may compensate for reduced C9ORF72 activity and other disease processes by increasing PI3P levels to facilitate the removal of glutamate receptors or DPRs (Fig. 6f) . Notably, FIG4 is a phosphatase that opposes PIKFYVE kinase by converting PI(3,5)P 2 to PI3P and loss-of-function mutations in FIG4 cause ALS 53 . Thus, genetic evidence suggests that PIKFYVE inhibition may be capable of modulating ALS disease processes in humans.
To verify that PIKFYVE is the functional target of the inhibitor, we first confirmed PIKFYVE expression by qPCR in control and patient (n = 3 patients) iMNs (Supplementary Fig. 15b ). Next, we verified that YM201636 rescued C9ORF72 patient iMN survival in a dosedependent manner (Supplementary Fig. 15c ). We then asked whether Apilimod, a structurally distinct PIKFYVE inhibitor, could rescue patient iMN survival 49 (Fig. 6b) . To verify target engagement by Apilimod in iPSC-derived motor neurons, we administered Apilimod for 3 h and measured EEA1 + early endosome size. PIKFYVE inhibition increases PI3P levels, leading to increased recruitment of EEA1 to early endosomes, more homotypic early endosomal fusion and larger EEA1 + early endosomes 52 . As expected, Apilimod treatment increased EEA1 + endosome size in a dose-dependent manner, verifying target engagement in motor neurons (Supplementary Fig. 15d,e) .
Consistent with PIKFYVE being the relevant target in the iMN survival assay, Apilimod increased C9ORF72 patient, but not control, iMN survival in both neurotrophic withdrawal (Fig. 6d) and excess glutamate conditions (n = 4 patients, n = 3 controls; Supplementary  Fig. 15f,g ). Automated neuron tracking software independently © 2018 Nature America, Inc., part of Springer Nature. All rights reserved. a r t i c l e s nature medicine VOLUME 24 | NUMBER 3 | MARCH 2018 3 2 1
verified Apilimod efficacy on C9ORF72 patient iMNs ( Supplementary  Fig. 15h ). As further confirmation that PIKFYVE was the active target, ASO-mediated suppression of PIKFYVE also rescued C9ORF72 patient iMN survival ( Fig. 6d and Supplementary Fig. 15i ). In addition, we synthesized a structural analog of Apilimod with a reduced ability to inhibit PIKFYVE kinase activity in a biochemical assay using purified PIKFYVE protein ( Fig. 6b and Supplementary Figs. 15j and 16 ).
The reduced activity analog was significantly less effective at rescuing C9ORF72 patient iMN survival (Fig. 6e) . Thus, small molecule inhibition of PIKFYVE can rescue patient motor neuron survival.
To verify that PIKFYVE-dependent modulation of vesicle trafficking was responsible for rescuing C9ORF72 patient iMN survival, we tested the ability of a constitutively active RAB5 mutant to block C9ORF72 patient iMN degeneration. Active RAB5 recruits PI3-kinase to synthesize PI3P from PI and, similar to PIKFYVE inhibition, increases PI3P levels 54 . Constitutively active RAB5 did not improve control iMN survival (n = 2 controls; Supplementary  Fig. 15k ), but successfully rescued C9ORF72 patient iMN survival (n = 3 patients; Supplementary Fig. 15l ). In contrast, dominantnegative RAB5, wild-type RAB5 and constitutively active RAB7 did not rescue C9ORF72 patient iMN survival (n = 1, 3, 3 patients, respectively; Supplementary Fig. 14m-o) .
To determine whether PIKFYVE inhibition rescued patient iMN survival by reversing phenotypic changes caused by C9ORF72 haploinsufficiency, we measured glutamate receptor levels with and without PIKFYVE inhibitor treatment. PIKFYVE inhibition significantly lowered NR1 (NMDA receptor) and GLUR1 (AMPA receptor) levels in patient (n = 4 patients) and C9ORF72 +/− iMNs ( Supplementary Fig. 15p-s) . PIKFYVE inhibition also reduced electrophysiological activity in patient motor neurons (C9-ALS1) during glutamate treatment (Supplementary Fig. 15t ). To determine whether small molecule inhibition of Pikfyve rescues C9ORF72 disease processes in vivo, we first established an NMDA-induced hippocampal injury model in C9orf72-deficient mice. In control mice, hippocampal injection of NMDA caused neurodegeneration after 48 h, as we have shown previously 55 ( Supplementary Fig. 17a,b) . Consistent with C9orf72-deficient mice having elevated NMDA receptor levels (Fig. 4h,i and Supplementary Fig. 11a-d) , injection of NMDA caused significantly greater neurodegeneration in C9orf72 +/− and C9orf72 −/− mice than in controls (Fig. 6g,h) . Notably, co-administration of Apilimod rescued NMDA-induced neurodegeneration in C9orf72-deficient mice (Fig. 6g,h) .
To determine whether PIKFYVE inhibition rescues gain-of-function processes in vivo, we measured DPR levels in C9-BAC transgenic mice 56 with or without Apilimod treatment. Although it was not previously reported 56 , we observed significantly higher levels of glycine-arginine (GR)-positive punctae in hippocampal neurons in C9-BAC mice than in controls (Fig. 6j) using a previously validated poly(GR) antibody 11 . These data are consistent with findings in another published C9-BAC mouse model 14 , suggesting that poly(GR) may be a common feature of C9-BAC mice. We also detected a low level of poly(GR) in neurons from control mice (Fig. 6j) , which may have been derived from other repeat regions or proteins with short poly(GR) sequences. Nevertheless, GR + punctae levels were significantly higher in C9-BAC mouse neurons than in controls (Fig. 6j) . Notably, Apilimod treatment significantly reduced the number of GR + punctae in hippocampal neurons in C9-BAC mice after 48 h (Fig. 6i,j) . Thus, small molecule inhibition of PIKFYVE rescues both gain-and loss-of-function disease processes (Fig. 6k) induced by C9ORF72 repeat expansion in vivo.
DISCUSSION
Our results indicate that haploinsufficiency for C9ORF72 activity triggers neurodegeneration in C9ORF72 ALS, and this occurs by at least two mechanisms. First, reduced C9ORF72 activity causes the accumulation of glutamate receptors and excitotoxicity in response to glutamate. Although C9orf72 knockout mice do not display overt neurodegeneration 14, 18, 22 , these mice may be protected from excitotoxicity because they lack gain-of-function disease processes such as DPRs, which induce aberrant splicing and dysfunction of the EAAT2 glutamate transporter in astrocytes in vitro 12 and in C9ORF72 ALS patients 4, 27 . EAAT2 dysfunction causes glutamate accumulation in the cerebrospinal fluid of ALS patients 27 ; consistent with this notion, we found that poly(PR) expression in human astrocytes reduced their rate of glutamate uptake. By using human iMNs, mice and human post mortem tissue, we found, to the best of our knowledge for the first time, that reduced C9ORF72 activity modulates the vulnerability of human motor neurons to degenerative stimuli and our results establish a mechanistic link between the C9ORF72 repeat expansion and glutamate-induced excitotoxicity
We also found that reduced C9ORF72 activity induces iMN hypersensitivity to DPRs by impairing their clearance. This uncovers a more direct form of cooperative pathogenesis between gain-and loss-offunction mechanisms in C9ORF72 ALS and FTD. Through a potentially similar mechanism, reduced C9ORF72 levels can also facilitate cytoplasmic TDP-43 accumulation in mouse neurons 20 .
Although studies in mice have indicated that C9orf72 activity is important for myeloid cell function 14, 18 and implicated C9ORF72 in regulating autophagy 20, 21, 31, 37 , and a report in mouse neurons and zebrafish suggested that C9orf72 isoform A may modulate poly-Q Ataxin-2 toxicity 20 , our study provides the first direct evidence that gain-and loss-of-function C9ORF72 mechanisms cooperate to cause the degeneration of human motor neurons. Recent studies have shown that C9ORF72 isoform A, but not isoform B, can form a functional complex with SMCR8 and WDR41 (ref. 20) . However, given that both C9ORF72 isoforms rescue C9-ALS iMN degeneration in our assay, other mechanisms or protein interactions may underlie the rescue of patient iMNs.
Notably, our results establish a new approach for suppressing DPR protein toxicity and blocking C9ORF72 pathogenesis: restoring or replacing C9ORF72 activity. Although high levels of C9ORF72 isoform A may have slightly detrimental effects on control motor neuron survival, we have only observed this in neurons without C9ORF72 repeat expansion. Thus, we would not anticipate a harmful effect of forced C9ORF72 expression in C9ORF72 patients. In addition, a better understanding of the effects of forced C9ORF72 expression could inform safe development of this therapeutic strategy. For example, determining whether C9ORF72 accelerates turnover of DPR aggregates by stimulating autophagy could lead to identifying new therapeutic targets.
To the best of our knowledge, our results show for the first time that chemical or genetic modulators of vesicle trafficking can fully rescue iMN degeneration caused by the C9ORF72 repeat expansion. Previous studies have implicated several rare ALS or FTD mutations linked to these vesicle trafficking pathways, but by showing that C9ORF72 is haploinsufficient in ALS and FTD and demonstrating that perturbation of vesicle trafficking rescues C9ORF72 neurodegeneration our findings highlight mechanistic convergence in a large portion of ALS.
Our results highlight the importance of C9ORF72 protein function, RAB5 activity, PI3P levels and lysosomeal function as key therapeutic targets for C9ORF72 ALS and FTD. By generating PI3P, RAB5 drives early endosomal maturation and the initial stages of lysosomal biogenesis (Fig. 6f) 57 . PI3P is also important for autophagosome formation and autophagsome-lysosome fusion. Indeed, a previous study suggested that PIKFYVE inhibition may increase autophagic flux 51 , and this should be investigated in the context of motor neurons. Lossof-function mutations in two other genes whose proteins function to increase PI3P levels, ALS2 and FIG4, also cause ALS 1 . ALS2 encodes the RAB5 guanine exchange factor ALSIN 58 , whereas FIG4 converts PI(3,5)P2 into PI3P 53 (Fig. 6f) . In addition, proteins encoded by several other ALS genes have key roles in lysosomal biogenesis, including CHMP2B, OPTN and SQSTM1 (ref. 1). The fact that FIG4 and ALS2 loss-of-function mutations can cause ALS suggests that PIKFYVE inhibition or RAB5 activation may be capable of modulating ALS disease processes in humans.
In myeloid cells, endosomal-lysosomal trafficking regulates inflammatory cytokine release 49 , and C9orf72-deficient macrophages do indeed release inflammatory cytokines 18 . Notably, the PIKFYVE inhibitor Apilimod inhibits the release of the pro-inflammatory cytokines IL-12 and IL-23 from human and mouse peripheral blood mononuclear cells 49 . If impaired endosomal and lysosomal trafficking in C9ORF72 patients increases the production of pro-inflammatory cytokines that accelerate disease progression 18 , PIKFYVE inhibitors or other modulators of this pathway may provide therapeutic benefit by lowering cytokine release.
We anticipate three key implications of our findings: ALS and FTD caused by the C9ORF72 repeat expansion require both gain-and lossof-function mechanisms, increasing C9ORF72 activity in motor neurons should mitigate disease and provides a new therapeutic target, and PIKFYVE inhibition and other approaches that modulate vesicle trafficking may ameliorate C9ORF72 disease processes in both neurons and myeloid cells. The fact that mutations in FIG4 cause ALS, epilepsy and Charcot-Marie-Tooth 53 illustrates the broad implications of impaired vesicle trafficking in the CNS. The identification of targets that effectively modulate vesicle trafficking in neurons, glia and myeloid cells could hold tremendous therapeutic value for C9ORF72 ALS and FTD and other CNS disorders.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. a r t i c l e s nature medicine VOLUME 24 | NUMBER 3 | MARCH 2018ONLINE METhODS iPSC reprogramming. Human lymphocytes from healthy subjects and ALS patients were obtained from the NINDS Biorepository at the Coriell Institute for Medical Research and reprogrammed into iPSCs as previously described using episomal vectors 59 . Briefly, mammalian expression vectors containing Oct4, Sox2, Klf4, L-Myc, Lin28, and a p53 shRNA were introduced into the lymphocytes using the Adult Dermal Fibroblast Nucleofector Kit and Nucleofector 2b Device (Lonza) according to the manufacturer's protocol. The cells were then cultured on mouse feeders until iPSC colonies appeared. The colonies were then expanded and maintained on Matrigel (BD) in mTeSR1 medium (Stem Cell Technologies).
Repeat primed PCR (RP-PCR).
To provide a quantitative measure of (GGGGCC) n hexanuceotide expansion in C9ORF72, 100 ng of genomic DNA was amplified by touchdown PCR using primers shown in Supplementary Table 4 , in a 28-µl PCR reaction consisting of 0.2 mM each of 7-deaza-2-deoxyguanine triphosphate (deaza-dGTP) (NEB), dATP, dCTP and dTTP, 7% DMSO, 1X QSolution, 1X Taq PCR buffer (Roche), 0.9 mM MgCl 2 , 0.7 µM reverse primer (four GGGGCC repeats with an anchor tail), 1.4 µM 6FAM-fluorescently labeled forward primer, and 1.4 µM anchor primer corresponding to the anchor tail of reverse primer (Supplementary Table 4) . During the PCR, the annealing temperature was gradually decreased from 70 °C and 56 °C in 2 °C increments with a 3-min extension time for each cycle. The PCR products were purified using the QiaQuick PCR purification kit (Qiagen) and analyzed using an ABI3730 DNA Analyzer and Peak Scanner Software v1.0 (Life Technologies).
C9ORF72 Southern blotting.
A 241-bp digoxigenin (DIG)-labeled probe was generated from 100 ng control genomic DNA (gDNA) by PCR reaction using Q5 High-Fidelity DNA Polymerase (NEB) with primers shown in Supplementary Table 4. Genomic DNA was harvested from control and patient iPSCs using cell lysis buffer (100 mM Tris-HCl pH 8.0, 50 mM EDTA, 1% w/v sodium dodecyl sulfate (SDS)) at 55 °C overnight and performing phenol:chloroform extraction. A total of 25 µg of gDNA was digested with XbaI at 37 °C overnight, run on a 0.8% agarose gel, then transferred to a positive charged nylon membrane (Roche) using suction by vacuum and UV-crosslinked at 120 mJ. The membrane was prehybridized in 25 ml DIG EasyHyb solution (Roche) for 3 h at 47 °C then hybridized at 47 °C overnight in a shaking incubator, followed by two 5-min washes each in 2× Standard Sodium Citrate (SSC) and in 0.1% SDS at 23 °C, and two 15-min washes in 0.1× SSC and in 0.1% SDS at 68 °C. Detection of the hybridized probe DNA was carried out as described in DIG System User's Guide. CDP-Star Chemilumnescent Substrate (Sigma-Aldrich) was used for detection and the signal was developed on X-ray film (Genesee Scientific) after 20 to 40 min.
Molecular cloning and viral production.
Complementary DNAs (cDNAs) for the iMN factors (Ngn2, Lhx3, Isl1, NeuroD1, Ascl1, Myt1l and Brn2) and iDA neuron factors (Ascl1, Brn2, Myt1l, Lmx1a and Foxa2), were purchased from Addgene. cDNA for C9ORF72 was purchased from Thermo Scientific. Each cDNA was cloned into the pMXs retroviral expression vector using Gateway cloning technology (Invitrogen). The Hb9::RFP lentiviral vector was also purchased from Addgene (ID: 37081). Viruses were produced as follows. HEK293 cells were transfected at 80-90% confluency with viral vectors containing genes of interest and viral packaging plasmids (PIK-MLV-gp and pHDM for retrovirus; pPAX2 and VSVG for lentivirus) using polyethylenimine (PEI)(Sigma-Aldrich). The medium was changed 24 h after transfection. Viruses were harvested at 48 h and 72 h after transfection. Viral supernatants were filtered with 0.45 µM filters, incubated with Lenti-X concentrator (Clontech) for 24 h at 4 °C, and centrifuged at 1,500 g at 4 °C for 45 min. The pellets were resuspended in 300 µl DMEM + 10% FBS and stored at −80 °C.
Conversion of iPSCs into induced motor neurons and dopaminergic neurons.
Reprogramming was performed in 96-well plates (8 × 10 3 cells/well) or 13mm plastic coverslips (3.2 × 10 4 cells/coverslip) that were sequentially coated with gelatin (0.1%, 1 h) and laminin (2-4 h) at 23 °C. To enable efficient expression of the transgenic reprogramming factors, iPSCs were cultured in fibroblast medium (DMEM + 10% FBS) for at least 48 h and either used directly for retroviral transduction or passaged before transduction for each experiment. Seven iMN or five iDA factors were added in 100-200 µl fibroblast medium per 96-well well with 5 µg/ml polybrene. For iMNs, cultures were transduced with lentivirus encoding the Hb9::RFP reporter 48 h after transduction with transcription factor-encoding retroviruses. On day 5, primary mouse cortical glial cells from P1 ICR pups (male and female) were added to the transduced cultures in glia medium containing MEM (Life Technologies), 10% donor equine serum (HyClone), 20% glucose (Sigma-Aldrich), and 1% penicillin/streptomycin. On day 6, cultures were switched to N3 medium containing DMEM/F12 (Life Technologies), 2% FBS, 1% penicillin/streptomycin, N2 and B27 supplements (Life Technologies), 7.5 µM RepSox (Selleck), and 10 ng/ml each of GDNF, BDNF, and CNTF (R&D). The iMN and iDA neuron cultures were maintained in N3 medium, changed every other day, unless otherwise noted. 
Immunocytochemistry
Live imaging of M6PR-GFP + vesicles in iMNs.
iMNs were transduced with a lentvirus encoding M6PR-GFP and imaged at > 10 frames per s over the course of 60 s in a Zeiss LSM780 confocal microscope with environmental control. Quantification of vesicle movement was performed using Imaris, using automated detection and tracking of vesicles.
Super-resolution imaging of iMNs. Structured illumination microscopy (SIM) images were acquired using a Zeiss Elyra PS.1 system equipped with a 100× 1.46 NA or 63× 1.4NA objective. Acquisition was performed with PCO edge sCMOS camera and image reconstruction was done with built-in structured illumination model. Confocal microscopy images were acquired using Zeiss LSM800 microcopy with 63× 1.4NA objective or Zeiss LSM780 microcopy with 40× 1.1NA objective. Z stack images were done with a step size of 2.5 um. Further image process was done with Fiji.
Quantification of glutamate receptors. For neurites, Image J was used to automate detection of NR1 + and GLUR1 + puncta in a given are using a threshold of 30. For dendritic spines, Image J was used to quantify the Signal Intensity on dendritic spines, which were selected manually. Neurons from at least two biological replicates were quantified for every sample condition.
Whole-cell patch-clamp electrophysiology. Whole cell membrane potential and current recordings in voltage-and current-clamp configurations were made using an EPC9 patch clamp amplifier controlled with PatchMaster software (HEKA Electronics). Voltage-and current-clamp data was acquired at 50 kHz and 20 kHz, respectively, with a 2.9-kHz low-pass Bessel filter, while spontaneous action potential recordings were acquired at 1-kHz sampling frequency. For experiments, culture media was exchanged with warm extracellular solution consisting of (in mM): 140 NaCl, 2.8 KCl, 10 HEPES, 1 MgCl 2 , 2 CaCl 2 , and 10 glucose, with pH adjusted to 7.3 and osmolarity adjusted to 305 mOsm. Glass patch pipettes were pulled on a Narishige PC-10 puller and polished to 5-7-M resistance. Pipettes were also coated with Sylgard 184 (Dow Corning) to reduce pipette capacitance. The pipette solution consisted of (in mM): 130 potassium gluconate, 2 KCl, 1CaCl 2 , 4 MgATP, 0.3 GTP, 8 phosphocreatine, 10 HEPES, 11 EGTA, adjusted to pH 7.25 and 290 mOsm. Pipettes were sealed to cells in G-resistance whole-cell configuration, with access resistances typically between 10-20 M, and leakage currents less than 50 pA. Capacitance transients were compensated automatically through software control. For voltage clamp, cells were held at −70 mV. For Current-voltage traces, a P/4 algorithm was used to subtract leakage currents from the traces. Measurements were taken at 20-25 °C. Data was analyzed and plotted in Igor Pro 6 (WaveMetrics) using Patcher′s Power Tools plug-in and custom programmed routines. Current density was obtained by dividing the measured ion channel current by the cell capacitance. For control iMNs, 10/10 tested fired action potentials. For C9-ALS iMNs, 9/10 tested fired action potentials.
Multielectrode array recordings. Local field potentials (LFPs) were recorded from iPSC-derived motor neurons on days 17-21 in culture in six-well multielectrode chips (nine electrodes and one ground per well) using a MultiChannel Systems MEA-2100 multielectrode array (MEA) amplifier (ALA Scientific) with built-in heating elements set to 37 °C. Cells were allowed to acclimate for 5 min after chips were placed into the MEA amplifier, and after glutamate addition (10 µM final concentration). For 1 µM Apilimod treatments, chips were incubated for 35 min in a humidified incubator in the presence of the particular drug, then returned to the MEA amplifier and acclimated for 5 min before beginning recordings. For each condition, recordings (5 min baseline, 10 min glutamate and/or drug, 40-kHz sampling rate) were filtered between 1-500 Hz, and average LFP frequency per well was determined using the accompanying MC Rack software.
Neuromuscular junction assay.
Primary chick myoblasts were dissected from D11 chick embryos and plated onto plastic dishes pre-coated with 0.1% gelatin. After 3 d of culture in muscle medium containing F10 (Life Technologies), 10% horse serum, 5% chicken serum (Life Technologies), 0.145 mg/ml CaCl 2 (Sigma), and 2% Penicillin/Streptomycin, myoblasts were trypsinized and replated onto iMNs which were at days 15-18 post-transduction. The coculture was maintained in neuronal medium containing DMEM/F12, 2% B27, 1% GlutaMax and 1% Penicillin/Streptomycin, supplemented with 10 ng/ml BDNF, GDNF, and CNTF for 7 d to allow neuromuscular junctions to form. Videos were taken using Nikon Eclipse Tis microscope with NIS Element AR software. Light-stimulated contraction shown in Supplementary Figure 2j are representative of contraction observed in two biological replicates, with five contractile sites per replicate.
Induced neuron survival assay. Hb9::RFP + iMNs appeared between days 13-16 after retroviral transduction. RepSox was removed at day 17 and the survival assay was initiated. For the glutamate treatment condition, 10 µM glutamate was added to the culture medium on day 17 and removed after 12 h. Cells were then maintained in N3 medium with neurotrophic factors without RepSox. For the glutamate treatment condition with glutamate receptor antagonists, cultures were co-treated with 10 µM MK801 and CNQX, and 2 µM Nimodipine during the 12 h glutamate treatment. The antagonists were maintained for the remainder of the experiment. For the neurotrophic factor withdrawal condition, BDNF, GDNF, and CNTF were removed from the culture medium starting at day 17. Longitudinal tracking was performed by imaging neuronal cultures in a Nikon Biostation CT or Molecular Devices ImageExpress once every 24-72 h starting at day 17. Tracking of neuronal survival was performed using SVcell 3.0 (DRVision Technologies). Neurons were scored as dead when their soma was no longer detectable by RFP fluorescence. All neuron survival assays were performed at least twice, with equal numbers of neurons from three individual replicates from one of the trials being used for the quantification shown. All trials quantified were representative of other trials of the same experiment. When iMNs from multiple independent donors are combined into one survival trace in the Kaplan-Meier plots for clarity, the number of iMNs tracked from each line can be found in Supplementary Table 5. CRISPR/Cas9 genome editing of iPSCs. CRISPR/Cas9-mediated genome editing was performed in human iPSCs as previously described, using Cas9 nuclease 60 . To generate loss-of-function alleles of C9ORF72, control iPSCs were transfected with a sgRNA targeting exon 2 of the C9ORF72 gene. Colonies were picked on day 7 after transfection and genotyped by PCR amplification and sequencing of exon 2. Colonies containing a frameshift mutation were clonally purified on MEF feeders and the resulting clones were re-sequenced to verify the loss-of-function mutation in C9ORF72.
Quantitative real time PCR. Total RNA was extracted from sorted iMNs at day 21 post-transduction with Trizol RNA Extraction Kit (Life Technologies) and reverse transcribed with an Oligo dT primer using ProtoScript II First Strand Synthesis Kit (NEB). RNA integrity was checked using the Experion system (BioRad). Real-time PCR was performed with iTaq Universal SYBR Green Supermix (Bio-Rad) using primers shown in Supplementary Table 4. Western blotting. iMNs from healthy controls and ALS patients were collected on day 21 post-transduction in RIPA buffer (Sigma-Aldrich) with a protease inhibitor cocktail (Roche). Protein quantity was measured by the BCA assay (Pierce) and samples were run on a 10% SDS gel at 4 °C. The gel was transferred onto an Immobilon membrane (Millipore). The membrane was blocked with 5% milk in 0.1% PBS-Tween 20 (PBS-T)(Sigma-Aldrich), incubated with primary antibodies overnight at 4 °C, washed three times with 0.1% PBS-T, then incubated with horseradish peroxidase (HRP)-conjugated (Santa Cruz). After three washes with 0.1% PBS-T, blots were visualized using an Amersham ECL Western Blotting Detection Kit (GE) or the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo) and developed on X-ray film (Genesee). The following primary antibodies were used: rabbit anti-C9ORF72 (Proteintech, cat. no. 22637-1-AP, 1:1,000), mouse anti-GAPDH (Santa Cruz, cat. no. sc-32233, 1:1,000), chicken anti-MAP2 (Abcam, cat. no. ab11267, 1:10,000), mouse anti-FLAG (Sigma, cat. no. F1804, 1:1,000), rabbit anti-GLUR1 (Millipore, cat. no. 1504, 1:1,000), mouse anti-NR1 (Novus, cat. no. NB300118, 1:2,000), mouse anti-Transferrin receptor (Thermo, cat. no. 136800, 1:1,000), mouse anti-LAMP3 (DSHB, cat. no. H5C6, 1:1,000), rabbit anti-LAMP3 (Proteintech, cat. no. 12632, 1:1,000), mouse anti-LAMP2 (DSHB, cat. no. H4B4, 1:4000), mouse anti-LAMP1 (Abcam, cat. no. Ab25630, 1:1,000), goat anti-HRP (Santa Cruz, cat. no. sc-47778 HRP, 1:4,000), mouse anti-EEA1 (BD Biosciences, cat. no. BD610457, 1:1,000), mouse anti-TUJ1 (Biolegend, cat. no. MMS-435P, 1:5,000), rabbit anti-APP (Abcam, cat. no. ab32136, 1:10,000), mouse anti-Tau5 (Thermo, cat. no. AHB0042, 1:1,000), mouse anti-PSD-95 (Thermo, cat. no. MA1-045, 1:1,000), mouse anti-p53 (Cell Signaling, cat. no. 2524S, 1:1,000), anti-mouse HRP (Cell Signaling, cat. no. 7076S, 1:5,000), anti-rabbit HRP (Cell Signaling, cat. no. 7074S, 1:5,000). For C9ORF72 western blots, to generate enough motor neurons for C9ORF72 protein detection, we used a directed differentiation method described previously 28 .
Postsynaptic density extraction. Postsynaptic density extraction was done following a protocol published previously 61 . Briefly, mouse spinal cord tissue or human cortical tissue was homogenized in cold Sucrose Buffer (320 mM Sucrose, 10 mM HEPES pH 7.4, 2 mM EDTA, 30 mM NaF, 40 mM β-Glycerophosphate, 10 mM Na 3 VO 4 , and protease inhibitor cocktail (Roche)) using a tissue grinder and then spun down at 500 g for 6 min at 4 °C. The supernatant was re-centrifuged at 10,000 g for 10 min at 4 °C. The supernatant was collected as the 'Total' fraction, and the pellet was resuspended in cold Triton buffer (50 mM HEPES pH 7.4, 2 mM EDTA, 50 mM NaF, 40 mM β-Glycerophosphate, 10 mM Na 3 VO 4 , 1% Triton X-100 and protease inhibitor cocktail (Roche)) and then spun down at 30,000 RPM using a Beckman rotor MLA-130 for 40 min at 4 °C. The supernantant was collected as the 'Triton' fraction and the pellet was resuspended in DOC buffer (50 mM HEPES pH 9.0, 50 mM NaF, 40 mM β-Glycerophosphate, 10 mM Na 3 VO 4 , 20 µM ZnCl 2 , 1% sodium deoxycholate and protease inhibitor cocktail (Roche)) and collected as the "DOC", PSD-enriched fraction. Collected samples were boiled with SDS-PAGE sample buffer and analyzed by western blot. Purity of the PSD preps was analyzed by immunoblotting for PSD-95 (PSD), p53 (non-PSD), and synaptophysin (non-PSD).
Generation of Dox-NIL iMNs and biotinylation of surface-bound glutamate receptors. To generate Dox-NIL iMNs, the Dox-NIL construct was integrated into the AAVS1 safe harbor locus of the control, C9 +/− , and C9-ALS patient iPSC lines using CRISPR/Cas9 editing (gRNA sequence shown in Supplementary  Table 4) . Dox-NIL iMNs were generated by plating at ~25% confluency on matrigel coated plates and adding 1 µg/ml of doxycylin in N3 media +7.5 µM RepSox 1 d after plating. Mouse primary mixed glia were added to the cultures at day 6, and doxycyline was maintained throughout conversion. iMN cultures were harvested at day 17.
Biotinylation of plasma membrane localized glutamate receptors was performed using the Piece Cell Surface Protein Isolation Kit (Thermo Fisher Scientific) following the manufacturer's instructions. Briefly, Dox-NIL iMNs were incubated with 0.25mg/ml Sulfo-NHS-SS-Biotin in cold room for 1~2 h with end-to-end shaking. After quenching, cells were harvested by scraping and lysed with lysis buffer from the Piece Cell Surface Protein Isolation Kit or the M-PER mammalian protein extraction buffer (Thermo Fisher Scientific). Cell lysate was incubated with High Capacity NeutrAvidin agorase beads (Thermo Fisher Scientific), and the bound protein was eluted in 2X SDS-PAGE sample buffer supplemented with 50 mM DTT for 1 h at 23 °C with end-to-end rotation, and further analyzed by western blot.
Human astrocyte glutamate uptake assay. Human primary astrocytes from Lonza (cat. no. CC-2565) were cultured in Lonza Astrocyte Growth Medium (cat. no. CC-3186) according to the manufacturer's instructions. To force expression of dipeptide repeat proteins in the astrocytes, lentiviruses were produced in HEK 293T cells and concentrated ~80-fold using Lenti-X Concentrator (Clontech). When astrocytes reached 90% confluency, they were transduced with lentiviruses encoding either GFP or GR 50 -GFP. Fluorescence microscopy analysis was used to confirm that 60-80% of astrocytes were transduced in both conditions. To measure glutamate uptake, GFP-or GR 50 -GFP-expressing astrocytes were incubated with 200 mM glutamate in Astrocyte Growth Medium for 2 h at 37 °C in biological quadruplicate. Media samples were collected after 2 h and glutamate levels were quantified using the BioVision Glutamate Colorimetric Assay Kit (cat. no. K629) according to the manufacturer's instructions. Colorimetric substrate levels were quantified at 450 nm using a Molecular Devices SpectraMax i3x Multi-Mode Microplate Reader.
GST pull-down. Human EEA1 (1-209) with an N-terminal GST tag in pGEX-6P-1 vector or GST only were expressed in E. Coli BL21 (DE3) cells (Thermo Fisher Scientific) for 12 h at 18 °C. Harvested cells were lysed by sonication in cold GST Purification Buffer (50 mM Tris pH 8.0, 200 mM NaCl, 2 mM DTT, 0.5 mg/ml Lysozyme, 0.2% Triton X-100 and protease inhibitor cocktail (Roche)). After centrifugation at 15,000 g for 30 min at 4 °C, clarified lysate was incubated with glutathione sepharose 4B beads (GE Healthcare Life Science) for 3 h to purify GST-EEA1 or GST. HEK cells were transfected with C-terminal 3XFLAG tagged C9ORF72 isoform A or B, or eGFP constructs and harvested 36-48 h post-transfection in cold Lysis Buffer (25 mM HEPES pH 7.4, 100 mM NACl, 5 mM MgCl 2 , 1 mM DTT, 10% Glycerol, 0.1% Triton X-100 and protease inhibitor cocktail (Roche)).After centrifugation at 8,000 g for 10 min at 4 °C, the clarified supernatant was incubated with washed GST-EEA1 or GST beads for 2 h at 4 °C with end-to-end rotation. Beads were then boiled in 2× SDS-PAGE sample buffer and pulled-down protein was analyzed by western blot.
Percoll density gradient centrifugation. IPSC-MNs at differentiation D35 were harvested in cold Hypotonic buffer (20 mM HEPES pH 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM EDTA, 1mM EGTA, 1 mM DTT and protease inhibitor cocktail (Roche)) and lysed by passing through G25 needles 25 times and then spun down at 700 g for 10 min at 4 °C. The Supernatant was loaded onto pre-made 30% Percoll solution and re-centrifuged at 33,000 r.p.m. using Beckman rotor SWI55 for 50min at 4 °C. 300 ul aliquots were taken from top to bottom as fractions and all the collected samples were boiled with SDS-PAGE sample buffer and analyzed by western blot.
Membrane fraction isolation for immunoblot analysis of lysosomal protein levels. iMN cultures were harvested with the Plasma Membrane Isolation Kit (Abcam) according to the manufacturer's instructions.
Fluorescent in situ hybridization for RNA foci detection. Samples were first fixed in 4% PFA (1× PBS) overnight at 4 °C and were subsequently washed three times with 1× PBS. Next, cells were permeabilized with 0.3% Triton X-100 (1× PBS) for 10 min at 23 °C, followed by three washes with 1x PBS for 10 min each. After permeabilization, the samples were equilibrated in 1× SSC buffer for 10 min at 23 °C and then transferred into 50% formamide (2× SSC) for 10 min at 60 °C. The repeat expansion-targeting probe and the negative control probe were ordered from Exiqon 56 . During this step, the probe mixture (1 µl salmon sperm (10 µg/µl), 0.5 µl E. coli tRNA (20 µg/µl), 0.4 µl probe (25 µM), 25 µl 80% formamide/per sample) was made and placed at 95 °C for at least 10 min. The samples were submerged in 200 µl of hybridization buffer (4 ml 100% formamide, 0.5 ml 20× SSC, 1 ml BSA fraction V, 0.5ml RVC (20 mM), 1ml NaPO 4 (0.1 M), 3 ml nuclease-free water) and 27 µl of the probe mixture was added to each sample and incubated for 1 h at 60 °C. After probe hybridization, the samples were washed twice with 50% formamide (2× SSC) for 20 min each at 65 °C and once more with 40% formamide (1× SSC) for 10 min at 60 °C. The remaining formamide was removed by briefly washing with 1× SSC three times. A final crosslinking step was performed by first incubating the samples with 1× Tris-Glycine for 5 min followed by a 5-min incubation in 4% PFA. Samples were washed three times with 1× PBS, stained with DAPI, and imaged using a Zeiss LSM 800 confocal microscope.
GCaMP6 calcium influx assay. GCaMP6 was cloned into the pMXs-Dest-WRE retroviral vector and transduced into reprogramming cultures concurrently with the motor neuron factors. To assess GCaMP6 activity, 1.5 µm glutamate was added to iMN cultures and cells were imaged continuously for 2 min at 24 frames per s. GFP flashes were scored manually using the video recording. At least three different fields of view from three independent cultures, totaling 50-100 iMNs, were scored per condition.
Dipeptide repeat protein expression in iMNs and PR 50 -Dendra2 turnover analysis. To measure the effect of dipeptide repeat protein expression on iMN survival, PR 50 and GR 50 were cloned into the pHAGE lentiviral vector as fusions with GFP to allow tracking of protein expression. iMN cultures were transduced with PR 50 and GR 50 lentiviruses at day 17 of reprogramming and longitudinal survival analysis was started the same day. 10 ng/ml of GDNF, BDNF, and CNTF was maintained throughout the experiment, and glutamate treatment was not performed. To measure PR 50 turnover, PR 50 was cloned into the pHAGE lentiviral vector as a fusion with Dendra2 (Addgene). iPSC-derived fibroblasts were generated according to Daley and colleagues 62 . Briefly, when C9ORF72 −/− iPSC cultures reached 80% confluence, the medium was switched from mTeSR1 (Stem Cell Technologies) to human fibroblast medium containing DMEM (Life Technologies), 10% FBS (FBS)(Thermo Fisher Scientific), and 1% penicillin/ streptomycin (Life Technologies). Cells were passaged two to three times using Accutase (Life Technologies) before use in experiments. iPSC-derived fibroblasts were transduced with either pMXs-eGFP or pMXs-C9ORF72 isoform B-T2A-eGFP retrovirus and treated with 10 µg/ml mitomycin C for 3 h to inhibit cell proliferation. The cells were then transduced with the PR 50 -Dendra2 lentivirus and exposed to blue light for 1.5 s using a lumencor LED light source to initiate photoconversion. The amount of decay (as a fraction of the starting level) of the red fluorescent punctae was monitored by longitudinal time lapse imaging in a Molecular Devices ImageExpress and analyzed using SVCell 2.0 (DRVision Technologies). Fluorescence was quantified at t = 0 and 12 h after photoconversion. Distinct photoconverted punctae were treated as discrete objects for analysis (n = 20 each for +eGFP and +C9ORF72-T2A-eGFP). For each object, background fluorescence was subtracted and fluorescence was normalized according to object size. The fractional decay was statistically analyzed by twotailed Student's t test.
For iMN Dendra2 experiments, the same procedure was used except that PR 50 -Dendra2 lentivirus was transduced into iMN cultures at day 14 of conversion.
Small molecule screen and PIKFYVE inhibitor assays. Hb9::RFP + C9ORF72 ALS/FTD iMNs were generated in 96-well plates. On day 15 post transduction, neurotrophic factors and RepSox were withdrawn and the small molecule library was added (EMD Millipore kinase collection and Stemselect library, 3.3 µM final concentration) and added fresh every other day until the screen was terminated on day 25 post-transduction. Identification of neuroprotective compounds was identified using SVcell 3.0 (DRVision Technologies) and further verification by manual iMN tracking.
Synthesis and activity assays of Apilimod and the reduced activity analog. For experiments other than the comparison of Apilimod and the reduced-activity analog, Apilimod was purchased from Axon Medchem (cat. no. 1369). For the reduced-activity analog assays, Apilimod and the reduced activity analog were synthesized at Icagen, Inc. according to the schemes shown in Supplementary  Figure 16 . PIKFYVE kinase inhibition was measured using the ADP-Glo kinase assay from SignalChem according to the manufacturer's instructions, using purified PIKFYVE kinase (SignalChem cat. no. P17-11BG-05).
RNA sequencing. Libraries were prepared from total RNA using Clontech SMARTer Stranded RNA-Seq kit, with Clonetech RiboGone ribodepletion performed ahead of cDNA generation. Amounts of input RNA were estimated using the Bioanalyzer and libraries produced according to Clontech's protocol. Library generation and sequencing were performed at the Norris Cancer Center Sequencing Core at USC. All FASTQ files were analyzed using FastQC (version 0.10.1), trimmed using the FASTQ Toolkit (v 1.0), aligned to the GRCh37/hg19 reference genome using Tophat (version 2), and transcripts assembled and tested for differential expression using Cufflinks (version 2.1.1). Raw data is available for public download in the NCBI database under accession code PRJNA296854.
Bioinformatics analysis of gene expression. RNA sequencing output was aligned to the GRCh38 Reference Genome and quantified using the STAR aligner 63 . Genes were annotated against the GENCODE version 23 Comprehensive Gene Annotation. Quality control was performed using Picard Tools AlignmentSummaryMetrics. Samples passing quality control and having RNA Integrity Number (RIN) > 5 were used in downstream analysis. To identify differentially expressed genes, the R package DESeq2 was used as previously described 64 . The function DESeq was used to estimate size factors, estimate dispersion, fit the data to a negative binomial generalized linear model, and generate differential expression statistics using the Wald test. KEGG enrichment analysis was performed for internal analysis using the R package clusterProfiler 65 .
We compared the differential expression results from our data to other transcriptomic data sets in ALS, obtained from the Gene Expression Omnibus (GEO). Raw Affymetrix array data (.CEL files) were downloaded for data set GSE56504, and preprocessed using a standard exon array pipeline implemented using the R Bioconductor package oligo. For GSE56504, only the laser-capture microdissection samples were included/ Differential expression was calculated using the R Bioconductor package limma. RNA-seq counts data was obtained for data set GSE67196. For GSE67196, only the frontal cortex samples were included. Normalization and differential expression analysis were performed using DESeq2.
Code availability. Code for RNA sequencing analysis can be obtained from Verge Genomics by emailing alice@vergegenomics.com.
Retinoic acid/purmorphamine protocol for iPSC-motor neuron differentiation. iPSC motor neurons were generated as described previously 28 , with slight modifications. On day 0, iPSCs were dissociated with Accutase (Life Technologies) and 300,000 iPSCs were seeded into one Matrigel (Corning)-coated well of a six-well plate in mTeSR medium (Stem Cell Technologies) with 10 µM Rock Inhibitor (Selleck). On day 1, the medium was changed to Neural Differentiation Medium (NDM) consisting of a 1:1 ratio of DMEM/F12 (Genesee Scientific) and Neurobasal medium (Life Technologies), 0.5× N2 (Life Technologies), 0.5× B27 (Life Technologies), 0.1 mM ascorbic acid (Sigma), 1× Glutamax (Life Technologies). 3 µM CHIR99021 (Cayman), 2 µM DMH1 (Selleck) and 2 µM SB431542 (Cayman) were also added. On day 7, cells were dissociated with Accutase and 4.5 million cells were seeded into Matrigel coated 10-cm dishes in NDM plus 1 µM CHIR99021, 2 µM DMH1, 2 µM SB431542, 0.1 µM RA (Sigma), 0.5 µM Purmorphamine (Cayman) and 10 µM Rock Inhibitor. Rock inhibitor was removed on day 9. On day 13, cells were dissociated with Accutase and seeded at a density of 40 million cells per well in a non-adhesive six-well plate (Corning) in NDM plus 0.5 µM RA, 0.1 µM Purmorphamine, and 10 µM Rock Inhibitor. On day 19, the media was changed to NDM plus 1 µM RA, 1 µM Purmorphamine, 0.1 µM Compound E (Cayman), and 5 ng/ml each of BDNF, GDNF and CNTF (R&D Systems). Cells were used for experiments between days 25-35 of differentiation.
Electron microscopy. Cells were fixed in 6-well culture plates in 2.5% glutaraldehyde in 0.1M cacodylate buffer, post-fixed in 1% osmium tetroxide for 1 h and block stained in 1% uranyl acetate in 0.1 M acetate buffer pH 4.4 overnight at 4 °C. Dehydration was performed in increasing concentrations of ethanol (10%/25%/50%/75%/90%/100%/100%/100%) for 15 min each and infiltrated with increasing concentrations of Eponate12 (Ted Pella), 25% Eponate12 (no catalyst) in ethanol for 3 h, 50% overnight, 100% for 5 h, 100% overnight, and polymerized in fresh Eponate12 with DMP-30 for 48 h at 60 °C. Previously marked areas were sawed out, the tissue culture plastic was removed and the selected area sectioned parallel to the substrate at a thickness of 70 nm. Sections at a depth of 3-5 µm were collected on formvar-filmed 50 mesh copper grids and imaged at 80 kV in an FEI 208 Morgagni. Per micrograph, cytosol was used to quantify the number of electron dense spheres that were defined as lysosomes 38 .
Mouse immunostaining and quantification. All animal use and care were in accordance with local institution guidelines of the University Medical Center Utrecht and approved by the Dierexperimenten Ethische Commissie Utrecht with the protocol number DEC 2013.I.09.069. Wild-type C57BL6/J (strain: 000664), C9ORF72 KO (C57BL/6J-3110043021Rikem5Lutzy/J, strain: 027068), and C9-BAC (C57BL/6J-Tg(C9orf72_i3)112Lutzy/J, strain: 023099) were purchased from Jackson Laboratories (The Jackson Laboratory). Mice were housed in standard conditions with food and water ad libitum in the conventional vivarium at the University of Southern California. All animal use and care were in accordance with local institution guidelines of the University of Southern California and the IACUC board of the University of Southern California with the protocol numbers 20546 and 11938.
Previously described Nestin-Cre+/− C9orf72 loxP/loxP mice 22 (18 months old) and age-matched controls (n = 2 per genotype, 1 male and 1 female for C9orf72−/− and 2 males for C9orf72+/+) were transcardially perfused with phosphate buffered saline (PBS) and subsequently with 4% formaldehyde. Cryoprotection occurred in 30% sucrose. Additionally, 6 month old C9-BAC and wildtype controls were transcardially perfused with phosphate buffered saline (PBS) and subsequently with 4% formaldehyde. Cryoprotection occurred in 20% sucrose. After snap freezing, tissue was sectioned by cryostat at 20 µm thickness and stained with the following primary antibodies: NMDAR1, GluR1, GluR6/7, Lamp1, NeuN, Chat, and GR. Antigen retrieval by sodium citrate occurred before GR staining. Images were collected using a Zeiss LSM780 or LSM800 confocal microscope. Glutamate subunit intensity measurements occurred with ImageJ where the mean cytosolic intensity was divided by a background measurement collected near to the measured neuron. Lamp1 and GR quantification occurred with the help of ImageJ. The scientist performing the glutamate receptor subunit intensity, LAMP1 vesicle, and GR quantification was blinded to the genotypes or treatment of the samples.
NMDA/Apilimod hippocampal administration and NMDA-lesion site analysis. Mice were anesthetized with i.p. ketamine (100 mg/kg) and xylazine (10 mg/kg), and body temperature kept at 36.9 ± 0.1 °C with a thermostatic heating pad. Mice were placed in a stereotactic apparatus (ASI Instruments, USA) and the head is fixed accordingly. A burr hole was drilled, and an injection needle (33 gauge) was lowered into the hippocampus between CA1 and the dentate gyrus (AP −2.0, ML +1.5, DV −1.8). NMDA (10 or 20 nmol in 0.3 µl of phosphate-buffered saline, pH 7.4) was infused over 2 min using a micro-injection system (World Precision Instruments, Sarasota, FL, USA). Simultaneously, or independently, Apilimod (0.3 µl of 20 µM in phosphate-buffered saline, pH 7.4) was infused over 2 min using a micro-injection system (World Precision Instruments). The needle was left in place for an additional 8 min after the injection. Animals were euthanized 48 h later. Brains were quickly removed, frozen on dry ice, and stored at −80 °C until processing. 30-µm-thick coronal sections were prepared using a cryostat. Every fifth section 1 mm anterior and posterior to the site of injection was stained with cresyl violet. The lesion area was identified by the loss of staining, measured by NIH ImageJ software and integrated to obtain the volume of injury.
Immunohistochemistry of human tissue. Post mortem tissues were kindly provided by Neil Shneider (Columbia) and were collected from the following individuals: Sample 1 -age: 64, diagnosis: ALS, genotype: positive for C9ORF72 Statistical analysis. Analysis was performed with the statistical software package Prism Origin (GraphPad Software). Statistical analysis of iMN survival experiments was performed using a two-sided log-rank test to account for events that did not occur (that is, iMNs that did not degenerate before the end of the experiment). For each line, the survival data from 50 iMNs were selected randomly using Microsoft Excel, and these data were used to generate the survival curve. If all iMNs degenerated in a given experiment, statistical significance was calculated using a two-tailed Student's t test. For all other experiments, differences between two groups were analyzed using a two-tailed Student's t test, unless the data was non-normally distributed for which two-sided Mann-Whitney testing was used. Differences between more than two groups were analyzed by one way-ANOVA with Tukey correction for multiple testing. Significance was assumed at P < 0.05. Error bars represent the s.d. unless otherwise stated.
For all experiments, sample size was chosen using a power analysis based on pilot experiments that provided an estimate of effect size (https://www.stat.ubc. ca/~rollin/stats/ssize/n2.html). Mice used for immunohistochemical analysis were selected randomly from a set of genotyped animals (genotypes were known to investigators). Mouse and human tissue sections used for immunohistochemical analysis were selected randomly. For mouse tissues, sections were prepared using an approximately equal representation of all levels of the spinal cord, and of those, all were imaged and quantified. The sections were only not used if NeuN or Chat immunostaining failed. For iMN survival assays, assays were repeated at least twice, with each round containing 3 biologically independent iMN conversions. iMNs from the 3 biologically independent iMN conversions in one representative round was used to generate the Kaplan-Meier plot shown. iMN survival times were confirmed by manual longitudinal tracking by an individual who was blinded to the identity of the genotype and condition of each sample. To select 50 iMNs per condition for analysis, >50 neurons were selected for tracking randomly at day 1 of the assay. Subsequently, the survival values for 50 cells were selected at random using the RAND function in Microsoft Excel. For quantification of immunofluorescence, samples were quantified by an individual who was blinded to the identity of the genotype of each sample. iMN survival times were confirmed by manual longitudinal tracking by an individual who was blinded to the identity of the genotype and condition of each sample. All other quantification was performed by individuals blinded to the identity of each sample.
Additional reagent information.
The following antibodies were used in this manuscript: mouse anti-HB9 (Developmental Studies Hybridoma Bank); 81.5C10. chicken anti-TUJ1 (EMD Millipore); AB9354. rabbit anti-VACHT (Sigma); SAB4200559. rabbit anti-C9ORF72 (Sigma-Aldrich); HPA023873. rabbit anti-C9ORF72 (Proteintech); 25757-1-AP. mouse anti-EEA1 (BD Biosciences); 610457. mouse antiRAB5 (BD Biosciences); 610281. mouse anti-RAB7 (GeneTex); GTX16196. mouse anti-LAMP1 (Abcam); ab25630. mouse anti-M6PR (Abcam); ab2733. rabbit anti-GluR1 (EMD Millipore); pc246. mouse anti-NR1 (EMD Millipore); MAB363. chicken anti-GFP (GeneTex); GTX13970. rabbit anti-Glur6/7 (EMD Millipore); 04-921. mouse anti-FLAG (Sigma); F1804. mouse anti-GAPDH (Santa Cruz); sc-32233. chicken anti-MAP2 (Abcam); ab11267, rabbit anti-GLUR1 (Millipore, cat. no. 1504), mouse anti-NR1 (Novus, cat. no. NB300118), mouse anti-Transferrin receptor (Thermo, cat. no. 136800), mouse anti-LAMP3 (DSHB, cat. no. H5C6), rabbit anti-LAMP3 (Proteintech, cat. no. 12632), mouse anti-LAMP2 (DSHB, cat. no. H4B4), goat anti-HRP (Santa Cruz, cat. no. sc-47778 HRP), mouse anti-TUJ1 (Biolegend, cat. no. MMS-435P), rabbit anti-APP (Abcam, cat. no. ab32136), mouse anti-Tau5 (Thermo, cat. no. AHB0042), mouse anti-PSD-95 (Thermo, cat. no. MA1-045), mouse anti-p53 (Cell Signaling, cat. no. 2524S), anti-mouse HRP (Cell Signaling, cat. no. 7076S), anti-rabbit HRP (Cell Signaling, cat. no. 7074S).
HEK 293T cells were used to produce retrovirus, lentivirus, and C9ORF72 protein. HEK cells were used for these purposes based on previous published studies using HEK cells in order to produce viral particles and mammalian proteins. HEK cells were obtained from American Type Culture Collection, catalog number CRL-11268. HEK and iPS cells were tested for mycoplasma before, during, and after the study and were negative.
All experiments involving live vertebrates (cortical glial isolation) performed at USC were done in compliance with ethical regulations approved by the USC IACUC committee. All animal use and care at the University Medical Center Utrecht were in accordance with local institution guidelines of the University Medical Center Utrecht (Utrecht, the Netherlands) and approved by the Dierexperimenten Ethische Commissie Utrecht with the protocol number DEC 2013.I.09.069.
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Data exclusions
Describe any data exclusions. Inclusion/exclusion criteria are listed on page 48, "Methods" section, "Statistical analysis" subsection, paragraph 2.
Mice used for immunohistochemical analysis were selected randomly from a set of genotyped animals (genotypes were known to investigators). Mouse and human tissue sections used for immunohistochemical analysis were selected randomly. For mouse tissues, sections were prepared using an approximately equal representation of all levels of the spinal cord, and of those, all were imaged and quantified. The sections were only not used if NeuN or Chat immunostaining failed. For iMN survival assays, assays were repeated at least twice, with each round containing 3 biologically independent iMN conversions. iMNs from the 3 biologically independent iMN conversions in one representative round was used to generate the Kaplan-Meier plot shown. iMN survival times were confirmed by manual longitudinal tracking by an individual who was blinded to the identity of the genotype and condition of each sample. To select 50 iMNs per condition for analysis, the survival values for 50 cells were selected at random using the RAND function in Microsoft Excel. For quantification of immunofluorescence, samples were quantified by an individual who was blinded to the identity of the genotype of each sample.
Replication
Describe whether the experimental findings were reliably reproduced.
Experimental findings were reliably reproduced for all data in the manuscript.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For neuron survival assays, >50 neurons were selected for tracking randomly at day 1 of the assay. To select 50 iMNs per condition for analysis, the survival values for 50 cells were selected at random using the RAND function in Microsoft Excel. For other phenotypes, neurons were selected randomly for analysis.
Mice used for immunohistochemical analysis were selected randomly from a set of genotyped animals (genotypes were known to investigators). Mouse and human tissue sections used for immunohistochemical analysis were selected randomly. See page 48, "Methods" section, "Statistical analysis" subsection, paragraph 2.
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Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
iMN survival times were confirmed by manual longitudinal tracking by an individual who was blinded to the identity of the genotype and condition of each sample. All other quantification was performed by individuals blinded to the identity of each sample. See page 48, "Methods" section, "Statistical analysis" subsection, paragraph 3.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Image J was used to analyze immunoblot and immunostaining data. SVCell was used to analyze neuron survival assay images and is available under license agreement from DRVision Technologies, LLC. Graphpad Prism was used for graphing and statistical analysis. The Microsoft Excel RAND function was used to select iMNs for survival curve inclusion. DESeq2 was used for bioinformatic analysis, as well as proprietary code developed by and available from Verge Genomics.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
SVCell was used to analyze neuron survival assay images and is available under license agreement from DRVision Technologies, LLC. RNA seq analysis code was developed by and available from Verge Genomics.
